# A Multicentre Study in Otherwise Healthy Infants and Toddlers Hospitalised For and Diagnosed With RSV Lower Respiratory Tract Infection to Evaluate the Safety, Tolerability, and Clinical Activity of ALX-0171

> **NCT02309320** · PHASE1,PHASE2 · COMPLETED · sponsor: **Ablynx, a Sanofi company** · enrollment: 53 (actual)

## Conditions studied

- Respiratory Syncytial Virus Infection

## Interventions

- **BIOLOGICAL:** ALX-0171
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT02309320
- **Lead sponsor:** Ablynx, a Sanofi company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-12
- **Primary completion:** 2016-02
- **Final completion:** 2016-02
- **Target enrollment:** 53 (ACTUAL)
- **Last updated:** 2019-01-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02309320

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02309320, "A Multicentre Study in Otherwise Healthy Infants and Toddlers Hospitalised For and Diagnosed With RSV Lower Respiratory Tract Infection to Evaluate the Safety, Tolerability, and Clinical Activity of ALX-0171". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT02309320. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*